By Fineline Cube 
Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. This move is designed to secure funding for the advancement of its innovative pipeline of antibody-drug conjugates (ADCs).
Company Overview
BlissBio, established in 2017, is dedicated to developing next-generation ADCs to address critical unmet needs in oncology. The company’s lead candidate, BB-1701, is a HER2-targeted eribulin-based ADC. It is currently undergoing Phase II studies for the treatment of HER2+ breast cancer, non-small cell lung cancer (NSCLC), and other HER2-expressing malignancies.
Clinical Pipeline
In addition to BB-1701, BlissBio’s portfolio includes several other ADCs at early clinical stages:
- BB-1705: An EGFR-targeted ADC
- BB-1712: A B7-H3-targeted ADC
- BB-1709: A CD73-targeted ADC
These assets highlight BlissBio’s commitment to leveraging ADC technology to address various cancers.-Fineline Info & Tech